TTrialPathMatch Me to Trials
← Back to trials
RecruitingSmall Cell Lung Cancer

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Eligible age

18+ yrs

Accepts

All genders

Locations

9 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away

Sponsor: Merck Sharp & Dohme LLC

You may qualify if…

  • ✓ Has histologically or cytologically confirmed SCLC that is extensive stage (defined as Stage IV (T any, N any, M1a/b/c) following at least 1 prior line of systemic therapy that included platinum-based chemotherapy
  • ✓ Must be able to provide archival tumor tissue sample or fresh biopsy tissue sample
  • ✓ Human immunodeficiency virus (HIV) infected participants must have well controlled HIV on antiretroviral therapy (ART)

You may not qualify if…

  • ✕ Pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedure
  • ✕ Any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use except for a history of radiation pneumonitis that did not require steroids
  • ✕ Current history of ILD or clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
  • ✕ Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  • ✕ Active or history of immune deficiency with the exception of HIV-infected participants with well controlled HIV on ART
  • ✕ History within 6 months before the first dose of study intervention of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF) (New York Heart Association \> class II), and/or uncontrolled cardiac arrhythmia
  • ✕ History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before the first dose of study intervention
  • ✕ Active clinically significant infection requiring systemic therapy

Where it's recruiting

Colorado

Aurora

Florida

Miami

Illinois

Chicago

New Jersey

Hackensack

New York

Buffalo

Oregon

Portland

Tennessee

Nashville

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT06780137 · last updated 2026-10-06

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and · TrialPath